This book discusses new candidates for rapid-acting antidepressants,
such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3
antagonists and AMPA receptor agonists. There are serious limitations to
currently available antidepressants, such as delayed onset and low rates
of efficacy. The discovery that a single dose of ketamine, an NMDAR
antagonist, can produce rapid antidepressant effects that are sustained
has led to new research in this area. In this volume, a variety of novel
pharmaceutical treatments are examined. This volume would be useful to
both researchers and clinicians who work in the field of pharmacology,
specifically CNS drug treatments.